{
  "docId": "019de071-b6aa-745b-9366-85da01204b7f",
  "docSlug": "36e600bcc4f8cdbd41dc817cb6eec90e",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 91 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 5,
  "pageCount": 91,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b6aa-745b-9366-85da01204b7f/5",
  "deckHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f",
  "deckJsonHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f.json",
  "deckAnchorHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.74,
        "x": 0.25,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Subject to forward looking statements. Subsequent to 9/30/21, the Company drew down a net amount of $290M on the revolving credit facility. Trailing Twelve Months Adj. EBITDA (Non-GAAP) adjusted to exclude the contribution of ~$70M from the divested Amoun business over that period. Subject to receipt of applicable shareholder and other necessary approvals and the achievement of our target net leverage ratios (Bausch + Lomb <2.5x and Bausch Pharma ~6.5x-6.7x at the time of the spinoff).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b513b044-fa10-460c-ac11-68ae2470cf14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.48,
        "x": 0.47,
        "y": 0.0013
      },
      "kind": "list",
      "text": "We expect to launch the Solta Medical IPO in Dec. 2021/Jan. 2022 timeframe. We expect to launch the Bausch + Lomb IPO ~30 days after the Solta Medical IPO. Spinoff to occur following the expiry of customary lock-ups and achievement of our target net leverage ratios.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22df94c7-c472-4672-956c-8e2bd85b1502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.7,
        "y": 0.0063
      },
      "kind": "metric",
      "text": "6.4x total company net leverage, as of 9/30/21",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03eb1930-0b71-48f2-8b41-c11416325b3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.0063
      },
      "kind": "metric",
      "text": "$1.1B of debt repaid in 3Q21",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23e7fb2a-51ad-4074-91e7-aa717f9d1ec4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.38,
        "y": 0.0063
      },
      "kind": "metric",
      "text": "$1.6B YTD debt repayment as of 9/30/21",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5f3c98b-76e2-49af-a6e8-c27d265d94b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Accelerating Strategic Alternatives to Drive Shareholder Value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "290913e3-8c44-4f3d-94e8-cd60eabb256a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "ed0f37da-d094-4996-9a4a-05d6ec3aaa39",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The document starts with a clear agenda and key takeaways",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}